The USPTO issued patent US12596122B2 to The Board of Regents of the University of Texas System, granting exclusive intellectual property rights to LILRB2 antibodies for cancer and autoimmune disease applications. The patent includes claims covering the antibody compositions and methods of using them for detection and treatment purposes.

For pharmaceutical and biotechnology companies developing immunotherapies or antibody-based therapeutics, this patent may affect freedom-to-operate considerations. Entities conducting research in the LILRB2/ILT4 space should evaluate potential licensing needs or design-around strategies to avoid infringement on the granted claims.